Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
3(23%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
8%
Ph phase_2
3
23%
Ph phase_4
1
8%
Ph not_applicable
7
54%
Ph phase_1
1
8%

Phase Distribution

1

Early Stage

3

Mid Stage

2

Late Stage

Phase Distribution13 total trials
Phase 1Safety & dosage
1(7.7%)
Phase 2Efficacy & side effects
3(23.1%)
Phase 3Large-scale testing
1(7.7%)
Phase 4Post-market surveillance
1(7.7%)
N/ANon-phased studies
7(53.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

3

trials recruiting

Total Trials

13

all time

Status Distribution
Active(4)
Completed(2)
Terminated(2)
Other(5)

Detailed Status

unknown4
Recruiting3
Withdrawn2
Completed2
Not yet recruiting1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
3
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (7.7%)
Phase 23 (23.1%)
Phase 31 (7.7%)
Phase 41 (7.7%)
N/A7 (53.8%)

Trials by Status

withdrawn215%
completed215%
not_yet_recruiting18%
suspended18%
recruiting323%
unknown431%

Recent Activity

Clinical Trials (13)

Drug Details

Intervention Type
OTHER
Total Trials
13